Association between BRAF V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma
10.3760/cma.j.issn.0253-3766.2015.02.009
- VernacularTitle:鼠类肉瘤滤过性毒菌致癌同源体B1 V600 E基因突变与甲状腺乳头状癌中央区淋巴结转移的关系
- Author:
Chenlei SHI
1
;
Huadong QIN
;
Chao DING
;
Yu SUN
;
Yichen LYU
;
Tiefeng SHI
Author Information
1. 150086,哈尔滨医科大学附属第二临床医院普外四科
- Keywords:
Thyroid neoplasms;
BRAF V600E gene;
Mutation;
Lymph node;
Neoplasm
- From:
Chinese Journal of Oncology
2015;(2):123-127
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the association of concomitant BRAFV600E mutation with central lymph node metastases in papillary thyroid carcinoma ( PTC ) . Methods The clinicopathological data of 126 PTC patients who underwent surgical treatment within a period of 2 years were retrospectively analyzed. The BRAF V600E gene mutation was detected by quantitative fluorescence PCR. Results The BRAF mutation rate was 69. 0% (87/126). The univariate analysis showed that BRAF mutation status was significantly associated with central lymph node metastasis (P<0. 05), while the gender, multiple lesions, tumor size, extra?thyroidal invasion, Hashimoto′s thyroiditis and tumor stage were not significantly associated with the BRAF mutation (P>0. 05 for all). The multivariate analysis showed that only central lymph node metastasis was significantly correlated with BRAF mutation (P<0. 05). When the diameter of tumor was≤10 mm, BRAF mutation was statistically not significantly correlated to central lymph node metastasis ( P>0. 05). When the diameter of tumor was >10 mm, the central lymph node metastasis rate was significantly higher in patients with positive BRAF mutation than that in patients with a negative BRAF mutation ( P<0. 05). Conclusions The presence of BRAF mutation is an independent predictive factor for central lymph node metastasis. When PTC is with preoperative positive BRAF mutation, the cervical dissection should be routinely performed. The larger the tumor diameter is, the more important is the central lymph node dissection. There should be re?evaluated the necessity of preventative central lymph node dissection when the tumor diameter was ≤5 mm in patients with negative BRAF mutation.
